Corticotropin-Releasing Factor anti-inflammatory peptide data

In a 34-patient Phase I/II trial, Corticotropin-Releasing Factor (CRF) administered by continuous intravenous infusion over a four-hour period showed no statistically significant improvement in lung function, as measured by spirometry, between the treatment group and placebo.

NTII said the results don't necessarily rule out a role for CRF in asthma, because it's likely that efficacy would be seen only over a longer treatment period. The company is evaluating whether to begin another trial in this indication, as a two-week study giving the drug every day or every other day. ...